OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain
July 24, 2025Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain
OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …
Yourgene Health launches LightBench Discover for long-read sequencing labs
July 23, 2025Business Services, Technical Consultancy Devices, Novacyt, PacBio, Yourgene Health, molecular diagnostics
Yourgene Health, part of the Novacyt group, has announced the launch of LightBench Discover, an integrated benchtop instrument designed to …
Evestia Clinical and Atlantic Research Group merge to create global specialist CRO
July 23, 2025Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation
UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Takara and Macherey-Nagel enter distribution agreement for global expansion
July 22, 2025Mergers and Acquisitions Devices, Macherey-Nagel, Microbiology, Takara, Takara Bio Europe
Takara Bio Europe has entered into a distribution agreement with Macherey-Nagel (MN), an analytical and bioanalytical product provider, to expand …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
July 21, 2025Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …
LDC strengthens healthcare focus with appointment of Amit Thaper as investment director
July 21, 2025Business Services, Industry Associations, Research and Development Corporate, Inicio Health, Investment Director, LDC, RDi
LDC, the private equity arm of Lloyds Banking Group, has strengthened its healthcare expertise with the appointment of Amit Thaper …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
July 18, 2025Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review
July 18, 2025Medical Communications Committee for Medicinal Products for Human USE, European Medicines Agency (EMA), Ixchiq, Pharmacovigilance Risk Assessment Committee (PRAC), Vaccine, Virology, chikungunya
After completing a safety review of Ixchiq – a vaccine for chikungunya – the European Medicines Agency’s (EMA) safety committee …
Addenbrooke’s hospital offers first self-service digital eye test
July 17, 2025Research and Development Addenbrooke's Hospital, Cambridge, Opthalmology, UK, eye test, ophthalmology
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing system – DigiVis DVA system …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
July 16, 2025Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
July 16, 2025Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …
Osivax publishes positive results from trial of influenza vaccine candidate
July 15, 2025Research and Development Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …
Pharvaris to report phase 3 data and submit New Drug Application
July 15, 2025Medical Communications, Research and Development Pharvaris, Rare Diseases, US Food and Drug Administration, clinical trial, genetic condition, new drug application
Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium
July 14, 2025Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …
Cube Biotech appoints Joachim Kreuzburg to its board of directors
July 11, 2025Research and Development Corporate, Cube Biotech, IBA Life Sciences, Sartorius, archimed, board of directors, membrane protein production
German-based Cube Biotech announced the appointment of Joachim Kreuzburg to its board of directors. This will support the development of …
NICE recommends NHS use of mirikizumab for Crohn’s disease
July 11, 2025Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial
Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
July 11, 2025Research and Development BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
